Parkinson Cannabis Trial: Clinically Meaningful Improvement Was Not Superiority to Placebo
Participants receiving CBD/THC improved on a Parkinson motor scale, but they did not improve significantly more than participants receiving placebo. A clinically meaningful within-group change and a treatment-specific benefit are different findings.
A randomized comparison
The phase II trial randomized 61 people with Parkinson disease to an oral CBD/THC formulation or placebo. Thirty-one received active treatment and thirty received placebo. Participants continued usual care, and the primary outcome was change in the motor section of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale.
The reported formulation and dosing produced daily exposure around 200 mg CBD and 6.6 mg THC. Findings concern that combination during a brief trial, rather than all cannabinoid products.
The apparent contradiction is statistical
The active group improved by a mean 4.57 points on the motor scale, passing the paper’s stated threshold for a minimally important change. Nevertheless, the between-group comparison was nonsignificant, p=0.379. The placebo group also improved.
A threshold describing how much change may matter to a patient does not determine whether the drug caused more improvement than the comparator. Reporting only the active group’s change would omit the trial’s main causal comparison.
The secondary pattern was not uniformly favorable
Several motor and nonmotor outcomes improved within one or both groups without demonstrating a treatment advantage. Some caregiver assessments concerning concentration, sleep-related distress and everyday functioning were less favorable with CBD/THC. Many adverse effects were mild, but their presence belongs in the account of tolerability.
Measured plasma cannabinoid exposure confirms a different question from efficacy. Detecting the administered compounds does not turn a null clinical comparison into a positive one.
Scope and limitations
The authors identify brief treatment, strong placebo response and imperfect matching of product appearance and odor as limitations. The result does not prove that no person with Parkinson disease can benefit from any cannabis formulation. It does show why an uncontrolled report of improvement should not replace a randomized comparison when describing this particular treatment.
For context, see our discussion of THC concentrations and the separate question of impairment.
Primary research
Ying Liu and colleagues. Short-term cannabidiol with delta-9-tetrahydrocannabinol in Parkinson disease: a randomized trial. Movement disorders : official journal of the Movement Disorder Society (2024). DOI: 10.1002/mds.29768.
